Immutep (IMMP) Share-based Compensation (2011 - 2026)
Immutep's (IMMP) quarterly Share-based Compensation came in at $1.1 million in Q2 2026, up 51.34% on a YoY basis from $745171.6 in Q2 2025, and up 51.34% quarter-over-quarter from $745171.6 in Q2 2025.
Analysis
Immutep (IMMP) Share-based Compensation (2011 - 2026) Analysis & Trends
Immutep (IMMP) has reported Share-based Compensation for 11 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation rose 51.34% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $4.4 million (up 62.38% YoY), and the FY2026 full-year result was $1.1 million, up 51.34% from the prior year.
- Share-based Compensation grew to $1.1 million in Q2 2026 per IMMP's latest filing, from $745171.6 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.3 million in Q2 2023 and bottomed at -$560483.5 in Q2 2022.
- Historically, Share-based Compensation has averaged $766793.5 across 5 years, with a median of $1.1 million in 2026.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation soared 338.68% in 2023, then sank 37.05% in 2025.
- Over 5 years, Share-based Compensation stood at -$560483.5 in 2022, then jumped by 338.68% to $1.3 million in 2023, then dropped by 11.51% to $1.2 million in 2024, then tumbled by 37.05% to $745171.6 in 2025, then soared by 51.34% to $1.1 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.1 million, $745171.6, and $1.2 million for Q2 2026, Q2 2025, and Q2 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Immutep | 52.57 Mn | 52.57 Mn | - | 1.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Mn |
| Jun 30, 2025 | 745,171.57 |
| Jun 30, 2024 | 1.18 Mn |
| Jun 30, 2023 | 1.34 Mn |
| Jun 30, 2022 | -560,483.55 |
| Dec 31, 2021 | 3.13 Mn |
| Jun 30, 2021 | -477,452.67 |
| Jun 30, 2020 | 1.13 Mn |
| Dec 31, 2019 | 2.35 Mn |
| Jun 30, 2015 | 292.00 |
| Jun 30, 2014 | 57,309.00 |
| Jun 30, 2011 | -31,925.89 |